Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

103.31 -0.12 (-0.12%)
Streaming Delayed Price Updated: 1:17 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
News headline image
Abbott Labs: The Healthcare Dividend Stock I'd Happily Hold Forever ↗
Abbott is the name behind many well-known products. 
Via The Motley Fool
News headline image
1 Momentum Stock with Exciting Potential and 2 Facing Headwinds
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial... 
Via StockStory
News headline image
Exact Sciences (EXAS): Buy, Sell, or Hold Post Q3 Earnings?
What a time it’s been for Exact Sciences. In the past six months alone, the company’s stock price has increased by a massive 152%, reaching $103.18 per share. This was partly due to its solid quarterly... 
Via StockStory
News headline image
The Era of the Titans: Q4 2025 Mega-Deal Surge and the 2026 Economic Map
As of February 6, 2026, the global financial landscape is still reverberating from a historic tectonic shift that occurred in the final months of last year. In the fourth quarter of 2025, the M&A... 
Via MarketMinute
Topics Artificial Intelligence Economy
Exact Sciences Stock Soars To 4-Year High Even As Wall Street Piles On Downgrades After Abbott Deal — Retail Traders Take Profits ↗
Via Stocktwits
News headline image
1 Growth Stock to Stash and 2 We Avoid
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Topics Climate Change
News headline image
The Best Dividend King to Buy With $150 ↗
The stock is near its 52-week low. 
Via The Motley Fool
News headline image
Boston Scientific’s $14.5 Billion Stroke of Genius: Consolidation Heats Up in the Medtech Arms Race
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
3 Reasons to Buy This Dividend King After Its Steep Sell-Off ↗
Investors' reaction to this Dividend King's Q4 revenue miss was overdone. 
Via The Motley Fool
Topics Earnings
News headline image
Abbott Laboratories Shares Plunge 10% Following Q4 Revenue Miss and Diagnostics Weakness
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting... 
Via MarketMinute
Topics Economy
News headline image
Abbott Shares Slump as Revenue Miss and Exact Sciences Acquisition Jitters Overshadow Earnings Beat
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an... 
Via MarketMinute
Topics Earnings Economy
News headline image
$5.1 Trillion Global Surge: CEO Confidence Ignites New Era of M&A Transformation
The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase,... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
The Great Diagnostic Consolidation: How a $25.7 Billion Mega-Deal Ignited a 150% Surge in Healthcare M&A
As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial... 
Via MarketMinute
Topics Artificial Intelligence
News headline image
GRAIL Surges as Canaccord Genuity Sets Ambitious $105 Price Target Following Robust 2025 Growth
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an... 
Via MarketMinute
News headline image
Adaptive Biotechnologies Surges as Preliminary 2025 Results Signal a Turning Point in MRD Commercialization
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that... 
Via MarketMinute
News headline image
Biodesix Shares Rocket 42% on Record FY2025 Results and Path to Profitability
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025... 
Via MarketMinute
Topics Artificial Intelligence Death
News headline image
3 Mid-Cap Stocks We Steer Clear Of
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
1 High-Flying Stock on Our Watchlist and 2 We Question
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
3 Unpopular Stocks We Steer Clear Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps... 
Via StockStory
News headline image
1 Healthcare Stock for Long-Term Investors and 2 We Avoid
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance, and over the past six months, the... 
Via StockStory
Topics Stocks
News headline image
3 Overrated Stocks That Concern Us
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
Here's Why Grail Soared, Again, in November ↗
A combination of operational improvements and developments at its key rival bolstered the stock recently. 
Via The Motley Fool
News headline image
This Top Dividend King Just Became an Even Better Buy ↗
The healthcare leader wants to make waves in a potentially highly lucrative market. 
Via The Motley Fool
News headline image
Unusual volume stocks are being observed in Monday's session. ↗
Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session. 
Via Chartmill
News headline image
Q3 Earnings Highs And Lows: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Immuno-Oncology Stocks
As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
Biggest Stock Movers Today, Nov. 20: PACS, BBWI, & More ↗
On a big day for tech stocks, some other less well-known companies saw even larger moves. 
Via The Motley Fool
Topics Artificial Intelligence Stocks
News headline image
Why Exact Sciences Rallied Over 50% This Week ↗
The company received a buyout offer from Abbot Labs. 
Via The Motley Fool
News headline image
Why Exact Sciences Stock Surged Today ↗
A healthcare giant covets the cancer screening leader's technology. 
Via The Motley Fool
News headline image
Tech Stocks Fall Despite Nvidia's Beat, Walmart Jumps 6%: What's Moving Markets Thursday? ↗
Nvidia Corp. (NASDAQ:NVDA) delivered another blockbuster quarter and raised its outlook, but even that wasn't enough to lift Wall Street on Thursday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.